DAVIS JOHN C. JR 4

4 · Magenta Therapeutics, Inc. · Filed Dec 11, 2019

Form 4

Period: 2019-12-09

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2019-12-10$9.49/sh+17,055$161,852→ 25,359 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-12-09−4,614→ 254,099 total
Exercise: $9.49Exp: 2028-04-25→ Common Stock (4,614 underlying)
Sale
Common Stock
2019-12-10$15.00/sh−17,055$255,825→ 8,304 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-12-10−17,055→ 237,044 total
Exercise: $9.49Exp: 2028-04-25→ Common Stock (17,055 underlying)
Exercise/Conversion
Common Stock
2019-12-09$9.49/sh+4,614$43,787→ 12,918 total
Sale
Common Stock
2019-12-09$15.00/sh−4,614$69,210→ 8,304 total

Footnotes (3)

[F1]This trade is pursuant to an active 10b5-1 plan.
[F2]This transaction was executed in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
[F3]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

Documents

1 file